Bio-Plex Multiplex Assays

Mice are an optimal model organism for human cancer studies. However, when experiments involve a human xenograft in a mouse host, cross-reactivity presents a major concern in measuring biomarkers. This technical report evaluates 14 Bio-Plex Pro Human Cancer Biomarker Assays for cross reactivity to mouse proteins and discusses the resulting data.

A “device time-out” message on the Bio-Plex^® 200 System occurs when the instrument’s needle or probe cannot move correctly. Watch this video for several troubleshooting steps to try when this message occurs.

Bio-Rad’s new Bio-Plex Pro RBM Apoptosis Multiplex Assays enable complex, quantitative analyses of biomarkers in the intrinsic apoptosis pathway. Learn more about these biomarkers and view sample data and performance characteristics of these assays in this detailed technical report.

The high-throughput fluidics (HTF) alarm on the Bio-Plex^® 200 System indicates a problem with the instrument’s sheath fluid delivery system. See the actions needed to quickly resolve potential issues with this system and get back to your research!

During calibration of your Bio-Plex^® 200 System, you may receive a “failed to pressurize message.” In this short video, get some easy fixes for the most common issues prompting this message.

Design your customized Express or x-Plex assay, process your catalog number, and obtain pricing information, launch the Assay Builder

The Akt and MAPK signal transduction pathways are key areas of study for their roles in cell growth, function, and death, as well as for their possible roles in cancer development and diabetes. Bio-Rad’s new Bio-Plex Pro™ Akt and MAPK cell signaling assays enable researchers to study the activation of these key pathways as a response to various stimuli. This technical report validates the sensitivity and specificity of these assays after cells were exposed to insulin, EGF (epidermal growth factor), and UV radiation.

In an age of personalized medicine, getting the most out of highly targeted cancer therapies takes finding the best molecular targets for each patient. BioMarker Strategies LLC, a small startup, has been developing an innovative method to do this by modeling oncogenic pathway responses, but they needed to accurately measure the levels of phosphoproteins resulting from the activation of these genes. Learn how they are using the Bio-Plex multiplex immunoassay system to accurately quantify the proteins and generate functional signaling profiles for these oncogenes.

alt Melanoma is an aggressive cancer where early detection is essential for patient survival. The Facchiano lab is developing new anti-proliferation molecules against melanoma and is working to identify new molecular markers at the very early stages of pathology. Here Dr Antonio Facchiano discusses the merits of using the Bio-Plex technology to measure dose-dependent changes in expression levels of growth and angiogenic factors in cell lysates and supernatants.

Researchers at the Immaculate Dermopathic Institute (IDI-IRCCS, Rome) are using Bio-Plex technology in developing new anti-proliferation molecules and markers at the early stages of melanoma pathology. Dr Antonio Facchiano discusses how Bio-Plex has expedited the lab’s research.